Form 4: Cartesian Therapeutics Officer Exercises Stock Options Following Reverse Stock Split and Preferred Stock Conversion

Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, reports exercising stock options and converting preferred stock to common stock following a 1-for-30 reverse stock split.

Summary

• Christopher M. Jewell, the Chief Scientific Officer of Cartesian Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The filing reflects transactions occurring on April 8, 2024, following a 1-for-30 reverse stock split of the company's common stock.
• Jewell exercised stock options to acquire common stock and converted Series A Non-Voting Convertible Preferred Stock into common stock.
• The conversion of the Series A Preferred Stock occurred automatically after stockholder approval at a special meeting on March 27, 2024.
• Following the transactions, Jewell directly owns 25,940 shares of common stock.
• Jewell also holds options to purchase 33,265 shares of common stock that vest over time, and options to purchase 142,547 shares of common stock that are currently exercisable for 99,483 shares and will become exercisable for an additional 2,969 shares each month until June 16, 2025.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an officer. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The reverse stock split is a corporate action often undertaken to increase the stock price to meet exchange listing requirements or to improve investor perception.

Stakeholder Impact

• The reverse stock split and conversion of preferred stock could impact shareholders by altering the number of outstanding shares and potentially affecting the stock price.

Key Dates